Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

Background: Due to the relative rarity of small bowel adenocarcinoma (SBA), prospective trials, helping to guide therapeutic decisions, are lacking and the optimal therapy for advanced SBA is unknown. The role of targeted agents, such as anti–epidermal growth factor receptor (EGFR) and anti–vascular...

Full description

Bibliographic Details
Main Authors: Emanuela Dell’Aquila, Tea Zeppola, Marco Stellato, Francesco Pantano, Mario Scartozzi, Cristina Madaudo, Filippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile, Bruno Vincenzi, Roberto Moretto, Marco Puzzoni, Silvio Ken Garattini, Riccardo Lobefaro, Giuseppe Tonini, Daniele Santini
Format: Article
Language:English
Published: SAGE Publishing 2020-08-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.1177/1179554920946693

Internet

https://doi.org/10.1177/1179554920946693

Similar Items